Our focus is expanding affordable access to NARCAN® (naloxone HCl) Nasal Spray - the leading
community use naloxone - and progressing our pipeline of opioid overdose and addiction treatments.


Adapt Pharma Completes $95 Million Equity Financing U.S. Focused Specialty Pharmaceutical Company

May 2, 2014

Dublin, Ireland—May 2, 2014—Adapt Pharma Limited (“Adapt Pharma”) today announced that it has successfully completed a private placement of equity securities in an amount of U.S. $95 million.

Adapt Pharma was founded in late 2013 with the mission of creating a U.S.-focused specialty pharmaceutical company. Adapt Pharma will build a portfolio of established pharmaceutical brands and enhance their value through sales, marketing, and development activities. As the company develops, Adapt Pharma expects to add late‐stage clinical development projects specific to its therapeutic areas of interest.

“Our experienced management team, significant financial resources, and clear strategy provide a strong platform to execute on our mission,” commented Mr Seamus Mulligan, Adapt Pharma’s Chairman and Chief Executive Officer. Mr Mulligan further commented, “Our business is focused on the U.S. market and is led by the same team that founded Azur Pharma plc.” Azur Pharma merged with Jazz Pharmaceuticals plc in 2012.

About Adapt Pharma Limited

Adapt Pharma Limited is a privately held pharmaceutical company committed to making a positive impact on the lives of patients with specialty medical conditions. Adapt Pharma’s strategy is to identify, evaluate, selectively acquire, and enhance the value of late-stage development—and FDA approved—pharmaceutical products. Adapt Pharma’s company headquarters is in Dublin, Ireland.

Media Contact